- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
- Interventions
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Diagnostic Test · Drug · Other
- Lead sponsor
- Taproot Health
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Idaho Falls, Idaho • Laredo, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1849–1872
of 20,620
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma (MM)
- Interventions
- PET-enabled dual-energy CT imaging, X-ray dual-energy CT imaging
- Diagnostic Test
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Rheumatoid Arthritis, Osteoarthritis
- Interventions
- ITIS diet
- Dietary Supplement
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Hepatic Impairment
- Interventions
- AZD6234, AZD9550
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Chandler, Arizona • Rialto, California • Miami Lakes, Florida + 1 more
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Elsubrutinib, Placebo for elsubrutinib, Upadacitinib, Placebo for upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 47
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 40 more
- Conditions
- Type 1 Diabetes
- Interventions
- Control-to-Range Automated Insulin Management System
- Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 4
- States / cities
- Santa Barbara, California • Stanford, California • Aurora, Colorado + 1 more
- Conditions
- HIV/AIDS
- Interventions
- Tenofovir 300Mg Oral Tablet, Emtricitabine 200 MG
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, B-Cell
- Interventions
- VELCADE®, Rituximab, Cyclophosphamide, Decadron
- Drug
- Lead sponsor
- Oncology Specialists, S.C.
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 2
- States / cities
- Niles, Illinois • Park Ridge, Illinois
- Conditions
- Graft Versus Host Disease
- Interventions
- brentuximab vedotin, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
- Other
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Asthma, Domestic Violence
- Interventions
- Not listed
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma
- Interventions
- FT-1101, Azacitidine
- Drug
- Lead sponsor
- Forma Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Sarasota, Florida • Tampa, Florida + 5 more
- Conditions
- Leukemia
- Interventions
- filgrastim, oblimersen sodium, cytarabine, fludarabine phosphate
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Gulf War Syndrome, Gulf War Illness
- Interventions
- Not listed
- Lead sponsor
- Roskamp Institute Inc.
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Sarasota, Florida • Boston, Massachusetts
- Conditions
- HIV Infections, HIV Wasting Syndrome
- Interventions
- Thalidomide
- Drug
- Lead sponsor
- Celgene Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 13
- States / cities
- Greenbrae, California • Redwood City, California • San Diego, California + 9 more
- Conditions
- Pruritus
- Interventions
- Biopsy, Blood
- Procedure
- Lead sponsor
- Boston University
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lymphoma, Histiocytic Sarcoma, Follicular Dendritic Cell Sarcoma, Interdigitating Dendritic Cell Sarcoma
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Omaha, Nebraska
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- ABT-199, Ketoconazole
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • Lebanon, New Hampshire • Hackensack, New Jersey
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Teclistamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 587 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Duarte, California • Stanford, California + 14 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Obinutuzumab, Quality-of-Life Assessment, Venetoclax
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 864
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 552 more
- Conditions
- Atopic Dermatitis
- Interventions
- RVT-501 0.5% topical ointment
- Drug
- Lead sponsor
- Dermavant Sciences GmbH
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 12
- States / cities
- Anniston, Alabama • Irvine, California • Jacksonville, Florida + 7 more
- Conditions
- Lymphoma
- Interventions
- filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 104
- States / cities
- Palo Alto, California • Fort Collins, Colorado • Jacksonville, Florida + 69 more
- Conditions
- Urticaria
- Interventions
- Omalizumab, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 40
- States / cities
- Granada Hills, California • Long Beach, California • Los Angeles, California + 36 more
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
- Interventions
- tanespimycin, cytarabine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Systemic Lupus Erythematosus, SLE
- Interventions
- Mycophenolate Mofetil, Hydroxychloroquine or Chloroquine, Prednisone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 19
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 15 more